Temasek-backed mRNA vaccine developer Abogen raises US$300m from investors including SoftBank
Add BT as a preferred source[BEIJING] Chinese mRNA technology firm Suzhou Abogen Biosciences said on Monday it had raised US$300 million from investors including SoftBank Group Corp's Vision Fund to support the development of its potential Covid-19 shot and other drug candidates.
The capital raise, led by SoftBank Vision Fund and 5Y Capital, also attracted investors such as Chimera Abu Dhabi, Fortune Ocean and Mirae Asset Financial Group.
It came after Abogen received US$720 million in August from investors including Temasek Holdings and Hillhouse-backed GL Ventures.
The proceeds will also be used to improve its mRNA platform with technologies such as artificial intelligence, Abogen said in a statement.
Reuters reported on Friday (Nov 26), citing sources, that SoftBank was in the final stage of investment talks with Abogen and was interested in leading the capital raise.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Electricity tariff to rise significantly from July despite Iran deal: EMA
What’s wrong with Orchard Road? Experts weigh in on the street’s cachet and its future
‘I felt like dying’: Thai Singha beer scion speaks up after disclosure of alleged sexual abuse
Onitsuka Tiger pivots from Asics stripes to tap luxury market
